Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (megace) in selected patients with malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6, 2002, Pages 552-556

  Markovic, Svetomir ^a,h   Suman, Vera J ^a   Dalton, Robert J ^b   Woods, John E ^a   Fitzgibbons Jr , Robert J ^c   Wold, Lester E ^a   Buckner, Jan C ^a   Kugler, John W ^d   Mailliard, James A ^c   Rowland, Kendrith M ^e   Krook, James E ^b   Brown, David W ^f   Tirona, Maria Tria ^g   Creagan, Edward T ^a  

^a MAYO CLINIC   (United States)

^b Duluth CCOP   (United States)

^c MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^d Illinois Oncol Res Assoc CCOP   (United States)

^e Carle Cancer Center CCOP   (United States)

^f Toledo Community Hospital Oncology Program CCOP   (United States)

^g Saskatoon Cancer Center   (Canada)

^h Allan Blair Cancer Centre   (Canada)

Author keywords

Malignant melanoma; Megestrol acetate; Phase III trial

Indexed keywords

MEGESTROL ACETATE; PLACEBO;

ADULT; AGED; AMENORRHEA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HUMAN; IMPOTENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MEGESTROL ACETATE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL ANALYSIS;

EID: 0036898478     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212000-00003     Document Type: Article

References (6)

1. Schacter L, Rozencweig M, Canetta R, et al. Megestrol acetate: Clinical experience. Cancer Treat Rev 1989;16:4:9-63.
2. Neifeld JP. Endocrinology of melanoma. Semin Surg Oncol 1996;12:402-6.
3. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma. Arch Surg 1994;129:316-24.
4. Beretta G, Tabiadon D, Fossati P. Clinical evaluation of medroxyprogesterone acetate (MAP) in malignant melanoma. Cancer Treat Rep 1979;63:1200.
5. Creagan ET, Schutt AJ, Ahmann DL, et al. Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep 1982;66:1239-40.
6. Creagan ET, Ingle JN, Schutt AJ, et al. A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989;12:152-5.